2 completed. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 1 | 1 | Completed 1 |
Follow Refractory Leukemia: new trials by email Literature Review of Refractory Leukemia trials Research Report on Refractory Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm CD123 targeted CAR-NK cells - Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 / Phase 2 | Completed | Chongqing Precision Biotech Co., Ltd | 5 | 2024-03-28 | 2026-08-05 |
| Efficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML) Panobinostat/LBH589 - Refractory Leukemia, Acute Myelogenous Leukemia | Phase 2 | Completed | Novartis Pharmaceuticals | 59 | 2009-08-01 | 2017-02-23 |
Leukemia (2) · Leukemia, Myeloid, Acute (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Hematologic Neoplasms (1) · Histiocytic Disorders, Malignant (1) · Lymphoma (1) · Neoplasms by Site (1) · Skin Diseases (1) · Skin Neoplasms (1) · Skin and Connective Tissue Diseases (1)
Panobinostat (1)
Chongqing Precision Biotech Co., Ltd (1) · Novartis Pharmaceuticals (1)
Australia (1) · Belgium (1) · China (1) · France (1) · Germany (1) · Italy (1) · Peru (1) · South Korea (1) · Spain (1) · Switzerland (1) · Turkey (Türkiye) (1) · United Kingdom (1) · United States (1)
Jia Wei, M.D (1)
2008 (1)